Harmony Biosciences Holdings (HRMY) Deferred Taxes (2022 - 2026)

Harmony Biosciences Holdings (HRMY) has 5 years of Deferred Taxes data on file, last reported at -$3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Deferred Taxes rose 10.39% year-over-year to -$3.9 million; the trailing twelve-month figure through Mar 2026 stood at -$6.9 million (up 77.26% YoY), and the FY2025 full-year result was -$7.3 million, up 75.08% from the prior year.
• Deferred Taxes declined to -$3.9 million in Q1 2026, from $7.4 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $7.4 million in Q4 2025 to a low of -$14.3 million in Q2 2024.
• A 5-year average of -$4.2 million and a median of -$4.2 million in 2022 frame the typical range for Deferred Taxes.
• Across the five-year window, Deferred Taxes sank 697.68% in 2024 and soared 209.89% in 2025, its largest moves.
• Tracing HRMY's Deferred Taxes over 5 years: stood at -$4.3 million in 2022, then surged by 126.34% to $1.1 million in 2023, then slumped by 697.68% to -$6.7 million in 2024, then soared by 209.89% to $7.4 million in 2025, then tumbled by 152.37% to -$3.9 million in 2026.
• Business Quant data shows HRMY's Deferred Taxes at -$3.9 million in Q1 2026, $7.4 million in Q4 2025, and -$3.9 million in Q3 2025.